Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 5/20 | 0.36 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.36 |
| ▸ | CBL | P22681 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22833108 | 1.00 | CBLB (0.36) | CBLBCBLCCBLGABRG2GABRB3 | |
| SCHEMBL26338174 | 0.87 | CBLB (0.40) | CBLBCBLCCBL | |
| SCHEMBL32686437 | 0.87 | CBLB (0.35) | CBLBCBLCCBL | |
| SCHEMBL22832507 | 0.86 | CHRNA1 (0.33) | CBLBCBL | |
| SCHEMBL30374823 | 0.86 | HSD11B1 (0.35) | CBLBCBL | |
| SCHEMBL25262977 | 0.86 | HSD11B1 (0.35) | CBLBCBL | |
| SCHEMBL22832499 | 0.86 | CHRNA1 (0.33) | CBLBCBL | |
| SCHEMBL25311812 | 0.86 | HSD11B1 (0.35) | CBLBCBL | |
| SCHEMBL22832497 | 0.86 | CHRNA1 (0.33) | CBLBCBL | |
| SCHEMBL30520964 | 0.84 | HSD11B1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364670-B | Substituted benzyl-triazole compound for Cbl-b inhibition and further application thereof | 纽力克斯治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11401267-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3990117-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | Nurix Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114364670-A | Substituted benzyl-triazoles for Cbl-b inhibition and further uses thereof | 纽力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401267-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885CBL 1/4885 |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885CBL 1/4885 |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885CBL 1/4885 |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885CBL 1/4885 |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885CBL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.